全文获取类型
收费全文 | 1557篇 |
免费 | 82篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 12篇 |
妇产科学 | 20篇 |
基础医学 | 169篇 |
口腔科学 | 28篇 |
临床医学 | 130篇 |
内科学 | 622篇 |
皮肤病学 | 30篇 |
神经病学 | 134篇 |
特种医学 | 56篇 |
外科学 | 162篇 |
综合类 | 5篇 |
预防医学 | 47篇 |
眼科学 | 11篇 |
药学 | 53篇 |
中国医学 | 4篇 |
肿瘤学 | 161篇 |
出版年
2023年 | 24篇 |
2022年 | 22篇 |
2021年 | 52篇 |
2020年 | 31篇 |
2019年 | 41篇 |
2018年 | 47篇 |
2017年 | 45篇 |
2016年 | 41篇 |
2015年 | 42篇 |
2014年 | 63篇 |
2013年 | 41篇 |
2012年 | 92篇 |
2011年 | 96篇 |
2010年 | 51篇 |
2009年 | 52篇 |
2008年 | 75篇 |
2007年 | 87篇 |
2006年 | 79篇 |
2005年 | 91篇 |
2004年 | 77篇 |
2003年 | 102篇 |
2002年 | 81篇 |
2001年 | 42篇 |
2000年 | 46篇 |
1999年 | 32篇 |
1998年 | 13篇 |
1997年 | 10篇 |
1996年 | 12篇 |
1995年 | 10篇 |
1994年 | 8篇 |
1993年 | 9篇 |
1992年 | 16篇 |
1991年 | 15篇 |
1990年 | 12篇 |
1989年 | 11篇 |
1988年 | 7篇 |
1987年 | 12篇 |
1986年 | 9篇 |
1985年 | 7篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1979年 | 5篇 |
1978年 | 3篇 |
1976年 | 2篇 |
1970年 | 2篇 |
1969年 | 6篇 |
1968年 | 2篇 |
1967年 | 2篇 |
1966年 | 3篇 |
1956年 | 2篇 |
排序方式: 共有1651条查询结果,搜索用时 15 毫秒
61.
Ruthenium complexes containing two anilines or its derivatives, cis-[RuII(NH2C6H5)2(bpy)2]2+ ([1]2+) and cis-[RuII(NH2C6H4(4-CH3))2(bpy)2]2+ ([2]2+), were oxidized by four molar equivalents of (NH4)4[CeIV(SO4)4]·2H2O to give N1-phenylcyclohexa-3,5-diene-1,2-diimineruthenium(ii) complexes, cis-[RuII(NHC6H4NC6H5)(bpy)2]2+ ([4]2+) and cis-[RuII(NHC6H3(4-CH3)NC6H4(4-CH3))(bpy)2]2+ ([5]2+), respectively, through an N–C bond formation between two aniline ligands cis-coordinated to the ruthenium center.Four-electron oxidation of two anilines coordinated to a ruthenium(ii) center in a cis-form affords N1-phenylcyclohexa-3,5-diene-1,2-diimine through an N–C bond formation with N–H and C–H bond activation. 相似文献
62.
Kohno A Morishita Y Iida H Sakamaki H Yokozawa T Kitaori K Ozeki K Matsuo K Sao H 《International journal of hematology》2006,84(1):83-89
We hypothesized that reducing the dosage of prophylaxis for graft-versus-host disease (GVHD) would reduce the risk of relapse and toxicity after bone marrow transplantation (BMT) from human leukocyte antigen (HLA)-identical siblings. In a prospective phase II trial, 21 patients with leukemia and myelodysplastic syndrome underwent BMT from HLA-identical siblings and received GVHD prophylaxis consisting of low-dose (1.5 mg/kg per day) cyclosporin A (CSP) with short-term methotrexate (MTX) treatment. This low-dose group was compared with a group of retrospective control patients (n = 22) who received a standard CSP dosage (3.0 mg/kg per day) and MTX. One patient died of transplantation-related causes within 100 days. The regimen-related toxicity was quite tolerable. Although acute GVHD of grades II to III was more frequent in the low-dose group (47.6%) than in the control group (22.7%), the increase in acute GVHD did not significantly contribute to morbidity or mortality. There were no differences between the groups in the incidence and severity of chronic GVHD. The probabilities of relapse and survival of the groups were similar according to the risk for relapse at the time of transplantation. A prospective randomized study is required to determine whether low-dose or standard-dose CSP in combination with MTX is optimal for Japanese patients who undergo allogeneic BMT from HLA-identical siblings. 相似文献
63.
Yokota A Ozawa S Masanori T Akiyama H Ohshima K Kanda Y Takahashi S Mori T Nakaseko C Onoda M Kishi K Doki N Aotsuka N Kanamori H Maruta A Sakamaki H Okamoto S;Kanto Study Group for Cell Therapy 《Bone marrow transplantation》2012,47(1):95-100
To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after transplantation. The risk for developing tumors was 2.16-fold higher than that of the age- and sex-adjusted general population. The cumulative incidence of solid tumors at 10 years after allo-HSCT was 2.4%. The risk was significantly higher for tumors of the skin, oral cavity and esophagus (standard incidental ratio 40.23, 35.25 and 10.73, respectively). No increase in gastric, colon or lung cancer, despite being the most prevalent neoplasm in the Japanese, was observed. In multivariate analysis, occurrence of chronic GVHD and malignant lymphoma as a primary disease was associated with a higher risk for developing solid tumors. Eighteen patients are still alive, and their 5-year probability of survival since diagnosis of solid tumors is 59.7%. Our data suggest that the incidence and risk factors of secondary solid tumors in Japanese allo-HSCT recipients are comparable to those reported in Western countries and emphasize that the early detection of solid tumors has a crucial role in improving OS. 相似文献
64.
Ayato Murata Takuya Genda Takafumi Ichida Nozomi Amano Sho Sato Hironori Tsuzura Shunsuke Sato Yutaka Narita Yoshio Kanemitsu Yuji Shimada Katsuharu Hirano Katsuyori Iijima Ryo Wada Akihito Nagahara Sumio Watanabe 《World journal of gastroenterology : WJG》2016,22(33):7569-7578
AIM To clarify the association between aldo-keto reductase family 1 member B10(AKR1B10) expression and hepatocarcinogenesis after hepatitis C virus eradication.METHODS In this study,we enrolled 303 chronic hepatitis C patients who had achieved sustained virological response(SVR) through interferon-based antiviral therapy. Pretreatment AKR1B10 expression in the liver was immunohistochemically assessed and quantified as a percentage of positive staining area by using image-analysis software. A multivariate Cox analysis was used to estimate the hazard ratios(HRs) of AKR1B10 expression for hepatocellular carcinoma(HCC) development after achieving SVR. The cumulative incidences of HCC development were evaluated using Kaplan-Meier analysis and the log-rank test.RESULTS Of the 303 chronic hepatitis C patients,153(50.5%) showed scarce hepatic AKR1B10 expression,quantified as 0%,which was similar to the expression in control normal liver tissues. However,the remaining 150 patients(49.5%) exhibited various degrees of AKR1B10 expression in the liver,with a maximal AKR1B10 expression of 73%. During the median follow-up time of 3.6 years(range 1.0-10.0 years),8/303 patients developed HCC. Multivariate analysis revealed that only high AKR1B10 expression(≥ 8%) was an independent risk factor for HCC development(HR = 15.4,95%CI: 1. 8- 1 3 2. 5,P = 0. 0 1 2). T h e 5- y e a r c u m u l a t i v e incidences of HCC development were 13.7% and 0.5% in patients with high and low AKR1B10 expression,respectively(P 0.001). During the follow-up period after viral eradication,patients expressing high levels of AKR1B10 expressed markedly higher levels of alanine aminotransferase and α-fetoprotein than did patients exhibiting low AKR1B10 expression.CONCLUSION Chronic hepatitis C patients expressing high levels of hepatic AKR1B10 had an increased risk of HCC development even after SVR. 相似文献
65.
Saito N Suzuki T Sugito M Ito M Kobayashi A Tanaka T Kotaka M Karaki H Kobatake T Tsunoda Y Shiomi A Yano M Minagawa N Nishizawa Y 《Surgery today》2007,37(10):845-852
Purpose Total pelvic exenteration (TPE) is the standard procedure for locally advanced rectal cancer involving the prostate and seminal
vesicles. We evaluated the feasibility of bladder-sparing surgery as an alternative to TPE.
Methods Eleven patients with advanced primary or recurrent rectal cancer involving the prostate or seminal vesicles, or both, underwent
bladder-sparing extended colorectal resection with radical prostatectomy. The procedures performed were abdominoperineal resection
(APR) with prostatectomy (n = 6), colorectal resection using intersphincteric resection combined with prostatectomy (n = 4), and abdominoperineal tumor resection with prostatectomy (n = 1). Local control and urinary and anal function were evaluated postoperatively.
Results Cysto-urethral anastomosis (CUA) was performed in seven patients and catheter-cystostomy was performed in four patients. Coloanal
or colo-anal canal anastomosis was also performed in four patients. There was no mortality, and the morbidity rate was 38%.
All patients underwent complete resection with negative surgical margins. After a median follow-up period of 26 months there
was no sign of local recurrence, and ten patients were alive without disease, although distant metastases were found in three
patients. Five patients had satisfactory voiding function after CUA, and three had satisfactory evacuation after intersphincteric
resection (ISR).
Conclusion These bladder-sparing procedures allow conservative surgery to be performed in selected patients with advanced rectal cancer
involving the prostate or seminal vesicles, without compromising local control. 相似文献
66.
Kanamaru T Sakata K Nakamura Y Yamamoto M Ueno N Takeyama Y 《Surgical laparoscopy, endoscopy & percutaneous techniques》2007,17(4):262-266
PURPOSE: Laparoscopic choledochotomy on patients indicated for common bile duct exploration was carried out according to an algorithm for managing choledocholithiasis. This study describes retrospectively our method and evaluates a new cystic duct biliary decompression cannula (J-tube) as an alternative to the T-tube. METHODS: Patients with confirmed choledocholithiasis (n=46) underwent laparoscopic choledochotomy. The T-tube was inserted in cases with suspected retained stones after common bile duct clearance, and the J-tube (950-mm long, 4 Fr) with a tapered and J-shaped segment at the distal end was inserted in other cases. RESULTS: Only 1 case was converted to open surgery (success rate, 97.8%); the J-tube was inserted in 30 patients and the T-tube in 15. The median operation time, hospital stay, and the interval until removal of the tube were significantly shorter with J-tube than with T-tube cases. Bile leakage after surgery occurred in 4 J-tube and 2 T-tube cases with one residual stone in each case. CONCLUSIONS: The transcystic decompression tube is easily and safely inserted with the J-kit. Among several strategies currently available for the management of choledocholithiasis, laparoscopic choledochotomy with the use of the J-tube is one of the safest and most feasible methods. 相似文献
67.
68.
Haraguchi K Takahashi T Hiruma K Kanda Y Tanaka Y Ogawa S Chiba S Miura O Sakamaki H Hirai H 《Bone marrow transplantation》2004,34(7):595-602
Human Valpha24+ natural killer T (NKT) cells have an invariant T-cell receptor-alpha chain and are activated in a CD1d-restricted manner. Valpha24+ NKT cells are thought to regulate immune responses and to play important roles in the induction of allograft tolerance. In this report, we analyzed the recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation and its correlation with graft-versus-host disease (GVHD). Patients who received a dose-reduced conditioning regimen, antithymocyte globulin- or CAMPATH-1H-containing conditioning regimen were excluded. NKT cells were reconstituted within 1 month after transplantation in peripheral blood stem cell transplantation recipients, while their numbers remained low for more than 1 year in bone marrow transplantation (BMT) recipients. The number of Valpha24+ NKT cells in BMT recipients with acute GVHD was lower than that in patients without acute GVHD, and both the CD4+ and CD4- Valpha24+ NKT subsets were significantly reduced. With regard to chronic GVHD, BMT recipients with extensive GVHD had significantly fewer Valpha24+ NKT cells than other patients. Furthermore, the number of CD4+ Valpha24+ NKT cells was also significantly reduced in patients with chronic extensive GVHD. Our results raise the possibility that the number of Valpha24+ NKT cells could be related to the development of GVHD. 相似文献
69.
Kato M Horikoshi Y Okamoto Y Takahashi Y Hasegawa D Koh K Takita J Inoue M Kigasawa H Ogawa A Sasahara Y Kawa K Yabe H Sakamaki H Suzuki R Kato K 《Bone marrow transplantation》2012,47(10):1307-1311
A second SCT is generally accepted as the only potentially curative approach for ALL patients that relapse after SCT, but the role of second SCT for pediatric ALL is not fully understood. We performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. OS at 2 years was 29.4±3.7%, the cumulative incidence of relapse was 44.1±4.0% and non-relapse mortality was 18.8±3.5%. Relapse occurred faster after the second SCT than after the first SCT (117 days vs 164 days, P=0.04). Younger age (9 years or less), late relapse (180 days or more after first SCT), CR at the second SCT, and myeloablative conditioning were found to be related to longer survival. Neither acute GVHD nor the type of donor influenced the outcome of second SCT. Multivariate analysis showed that younger age and late relapse were associated with better outcomes. Our analysis suggests that second SCT for relapsed pediatric ALL is an appropriate treatment option for patients that have achieved CR, which is associated with late relapse after the first SCT. 相似文献
70.
Hironori Tsujimoto Hiroyuki Horiguchi Risa Takahata Satoshi Ono Yoshihisa Yaguchi Shinsuke Nomura Nozomi Ito Manabu Harada Hiromi Nagata Yusuke Ishibashi Keita Kouzu Satoshi Tsuchiya Yujiro Itazaki Seiichiro Fujishima Yoji Kishi Hideki Ueno 《Journal of gastroenterology and hepatology》2020,35(5):788-794